|
#
|
Title
|
Authors
|
Affiliations
|
Keywords
|
|
P401
|
Intratumoral expression of IL12 using the ZVex® dendritic cell-targeting lentiviral vector exerts potent anti-tumor effects via induction of multiple immune effectors, including CD8 T cell responses
|
Tina C. Albershardt1, Jardin Leleux1, Rebecca S. Reeves1, Jan ter Meulen1, Peter Berglund1
|
1Immune Design, Seattle, WA, USA
|
Antigen presenting cells | Dendritic cell | Inflammation | Tumor microenvironment | Targeted therapy | Tumor antigens | Cytokine | Immune adjuvant | Vaccine
|
|
P402
|
Chemotherapy Enhances Oncolytic Recombinant Poliovirus Efficacy
|
Jeffrey Bryant1, Michael Brown2, Matthias Gromeier2
|
1Duke University, Durham, NC, USA 2Duke University Medical Center, Durham, NC, USA
|
Chemotherapy | Regulatory T cell (Treg) | Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | Tumor antigens | Vaccine | Clinical study | Immune suppression
|
|
P403
|
Intratumoral administration of a multigene construct by electroporation can effectively modulate anti-tumor response in a murine B16.F10 model
|
Shawna Shirley1, Anandaroop Mukhopadhyay1, Christoph Burkart1, Jocelyn Wright1, Robert Pierce2, Jean Campbell2, David Canton1
|
1Oncosec Medical Incorporated, San Diego, CA, USA 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA
|
Tumor infiltrating lymphocytes (TILs) | T cell | Antigen presenting cells | Neoantigens | Tumor antigens | Cytokine | Gene expression | Dendritic cell | Tumor microenvironment
|
|
P404
|
Targeting T-cells to human cancer associated fibroblasts using an oncolytic virus expressing a FAP-specific T-cell engager
|
Brian Champion1, Joshua Freedman2, Rebecca Ashfield2, Margaret Duffy2, Alice Brown1, Leonard Seymour2, Kerry Fisher2
|
1PsiOxus Therapeutics Ltd, Abingdon, United Kingdom 2Oxford University, Oxford, United Kingdom
|
T cell | Tumor stroma | Tumor microenvironment | Targeted therapy | Solid tumors
|
|
P405
|
Harnessing pre-existing antiviral immunity to treat solid tumors
|
Nicolas Cuburu1, Rina Kim1, Sergio Pontejo2, Cynthia Thompson1, Douglas Lowy1, John Schiller1, John Schiller3
|
1National Cancer Institute, NIH, Bethesda, MD, USA 2National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA 3NCI/NIH, Bethesda, MD, USA
|
Solid tumors | Vaccine | Immune adjuvant | Tumor antigens | Tumor microenvironment | Neoantigens | T cell | Tumor infiltrating lymphocytes (TILs)
|
|
P406
|
Dissecting the mechanisms underlying antitumor effects of live oncolytic vaccinia and heat-inactivated vaccinia.
|
Weiyi Wang1, Peihong Dai1, Ning Yang1, Stewart Shuman1, Taha Merghoub1, Jedd Wolchok1, Liang Deng1
|
1Memorial Sloan Kettering Cancer Center, New York, NY, USA
|
Tumor infiltrating lymphocytes (TILs) | Monocyte/Macrophage | Dendritic cell | Myeloid cells | Antigen presenting cells | Checkpoint blockade
|
|
P407
|
In situ vaccination for cancer immunotherapy: treat locally, respond systemically
|
Nicole Steinmetz1, P. Jack Hoopes2, Mee Ree Sheen2, Chenkai Mao2, Scott Sieg1, Steven Fiering2, Patrick :Lizotte2, Amy Wen3
|
1Case Western Reserve University, Cleveland, NH, USA 2Geisel School of Medicine at Dartmouth, Lebanon, NH, USA 3Case Western Reserve University, Cleveland, OH, USA
|
Tumor microenvironment | Vaccine | Immune adjuvant | Tumor infiltrating lymphocytes (TILs)
|
|
P408
|
Tumor Cell-Intrinsic STING Signaling and Regulation of IFN-β Gene Expression
|
Blake Flood1, Leticia Corrales2, Thomas Gajewski1
|
1University of Chicago, Chicago, IL, USA 2Aduro Biotech, Chicago, IL, USA
|
Inflammation | Cytokine | Gene expression | Immune adjuvant | Tumor evasion
|
|
P409
|
Efficacious anti-melanoma immunity induced by OX40 ligand-expressing oncolytic adenovirus Delta-24-RGDOX
|
Hong Jiang1, Andrew Dong1, Caroline Carrillo1, Verlene Henry1, Xuejun Fan1, Yisel Rivera-Molina1, Francisco Puerta-Martinez1, Teresa Nguyen1, Karen Clise-Dwyer1, Frederick Lang1, Candelaria Gomez-Manzano1, Juan Fueyo1
|
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA
|
Tumor microenvironment | Checkpoint blockade | Targeted therapy | Antibody | Monocyte/Macrophage | Solid tumors | Vaccine
|
|
P410
|
Generation of therapeutic RNAs to induce immunogenic cell death and interferon expression in cancer cells
|
Jaewoo Lee1, Youngju Lee2
|
1Duke University Medical Center, Durham, NC, USA 2Duke University, Durham, NC, USA
|
Cytokine | Immune adjuvant | Inflammation | TLR | Tumor microenvironment
|
|
P411
|
Immunotherapy with BO-112, a novel double-stranded RNA-based agent, promotes tumor cell death and boosts T cell immunity in preclinical mouse models
|
Lourdes Planelles1, Angela Aznar2, MªJosé Gómez-Sánchez1, Mercedes Pérez-Olivares1, Saray Garasa2, Mercedes Pozuelo1, Ivan Márquez-Rodas3, Marisol Quintero1, Ignacio Melero2
|
1BIoncotech Therapeutics, Valencia, Spain 2Center for Applied Medical Research (CIMA) & University of Navarra, Pamplona, Spain 3Hospital General Universitario Gregorio Marañón, Madrid, Spain
|
TLR | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment
|
|
P412
|
Antitumor immunity in patients with locally advanced soft tissue sarcoma treated with hafnium oxide nanoparticles and radiation therapy
|
Jérôme Galon1, Marick Laé2, Juliette Thariat3, Sébastien Carrere4, Zsuzsanna Papai5, Martine Delannes6, Philippe Rochaix6, László Mangel7, Fabienne Hermitte8, Zoltán Sapi9, Tamas Tornoczky7, Vincent Servois2, Isabelle Birtwisle Peyrottes3, Raphaël Tetreau4, Marie-Christine Château4, Sébastien Paris10, Hervé Brisse2, Sylvie Bonvalot2
|
1INSERM, Paris, France 2Institut Curie, Paris, France 3Centre Antoine Lacassagne, Nice, France 4Centre Régional De Lutte Contre Le Cancer Paul Lamarque, Montpellier, France 5Medical Centre, Hungarian Defence Forces, Budapest, Hungary 6Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France 7Pecs University, Pecs, Hungary 8HalioDX, Marseille, France 9Semmelweis University, Budapest, Hungary 10Nanobiotix, Paris, France
|
Tumor microenvironment | Biomarkers | Radiotherapy | Solid tumors | Tumor infiltrating lymphocytes (TILs)
|
|
P413
|
Transforming immunologically “cold” tumor into “hot” tumor with hafnium oxide nanoparticles and radiation therapy
|
Sébastien Paris1, Audrey Darmon1, Ping Zhang1, Maxime Bergère1, Laurent Levy1
|
1Nanobiotix, Paris, France
|
Tumor microenvironment | Biomarkers | Tumor infiltrating lymphocytes (TILs) | Radiotherapy | Solid tumors
|
|
P414
|
PVSRIPO is an Interferon-Resistant, Immunotherapeutic Oncolytic Virus
|
Ross Walton1, Michael Brown1, Eda Holl1, David Boczkowski1, Vidya Chandramohan1, Smita Nair1, Matthias Gromeier1
|
1Duke University, Durham, NC, USA
|
Antigen presenting cells | Dendritic cell | Inflammation | Cytokine | Immune adjuvant | Solid tumors
|
|
P415
|
Upregulation of PD-L1 in tumor microenvironment is a resistance mechanism for oncolytic virus immunotherapy
|
Dmitriy Zamarin1, Jacob Ricca1, Anton Oseledchyk1, Mathieu Gigoux1, Taha Merghoub1, Jedd Wolchok1
|
1Memorial Sloan Kettering Cancer Center, New York, NY, USA
|
Checkpoint blockade | Tumor microenvironment | Vaccine
|